logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: News & Comments

Progenics: The FDA Accepted the NDA for Its Cancer Product Azedra® and Granted It Priority Review

Progenics Pharmaceuticals (PGNX)  has good news today. The U.S. Food and Drug Administration (FDA) has accepted for review the firm’s New Drug Application (NDA) for its product  Azedra®  for recurrent and/or unresectable  pheochromocytoma and paraganglioma  — rare neuroendocrine tumors. The FDA has also granted...

Read More

December 28, 2017

0

KITE Pharma: The Risk Versus the Reward

Indeed, Saving One Life is Important. Yet, Important Too is Saving Many Lives The Risk Vs. The Reward We keep repeating that the CAR-T treatment is created to stay, not because somebody loves the firms developing the CAR-T immunotherapy, but...

Read More

May 9, 2017

0

Who Is the New FDA Commissioner? What Happened to Roche's Immunotherapy Drug?

AT A GLANCE IMPORTANT NEWS A New FDA Commissioner The U.S. Senate Voted in Favor of Scott Gottlieb as the FDA Chief - Dr. Gottlieb, a medical doctor graduated from Mount Sinai - He held a high ranking position in...

Read More

May 11, 2017

0

Why Akebia Therapeutics' Stock is Outperforming

AKEBIA THERAPEUTICS? Akebia Therapeutics (AKBA) whose stock trades on the NASDAQ is outperforming. The firm’s drug vadadustat -- an oral hypoxia-inducible factor (HIF) stabilizer in Phase 3 trial for anemia associated with chronic kidney disease (CKD) is attracting attention, which...

Read More

May 16, 2017

0

Why Incyte's Product Epacadostat's Positive Results Are So Important

As a matter of fact, we consider   Incyte’s (INCY)  drug epacadostat's good results extremely important. The reason? Two facts are currently settled in researchers’ and oncologists’ minds. These are: 1. Checkpoint inhibitors require effective combination therapy to boost their...

Read More

May 22, 2017

0

GlycoMimetics: A Lot to Tell at the ASCO Meeting

GlycoMimetics (GLYN) is a development-stage biotechnology company focused on cancer and sickle cell disease. The firm’s most advanced drug, rivipansel, a pan-selectin antagonist , is being developed for vaso-occlusive crisis in sickle cell disease. The product is in a Phase 3...

Read More

May 25, 2017

0

Dana-Farber Institute and Array Pharmaceutical Scientists to Work Together

Yes. Dana-Farber Cancer Institute and Array Pharmaceuticals (ARRY)  announced an immuno-oncology collaboration with potential applicability in a wide range of cancer indications. Who are these people, meaning Danna-Faber Cancer institute ? Founded in 1947, Dana-Farber Cancer Institute in Boston, Massachusetts has...

Read More

February 2, 2016

0

Knowing Better About Gilead and Amgen. The Mess and Miss Following the Storm

Gilead Sciences Gilead (GILD) Shareholders wouldn’t expect to watch short investors make billions of dollars going against Gilead during this firm's most glorious times. We never imagined negative analysts could have the capability of persuading millions of shareholders to sell...

Read More

February 5, 2016

0

Regulus Offers Proof of Concept and Feasibility with Its HCV RNA Targeted Drug

Regulus Pharmaceuticals (RGLS)  a biopharmaceutical company that discovers, designs and develop treatments targeting  microRNAs  announced interim results from one of the company's ongoing Phase 2 studies of its hepatitis C virus (HCV) product  RG-101.  The study was designed to evaluate...

Read More

February 17, 2016

0

AERIE Pharmaceuticals: The Novel Glaucoma Eye Drops Confirm Their Superiority

On February 4, 2015, we wrote an article titled, “Aerie Pharmaceuticals is speeding towards improving the treatment of glaucoma”, posted under News & Comments at the Prohost website, we wrote the following: YOUNG BUT STRONG COMPETITOR IN THE GLAUCOMA HUGE...

Read More

February 18, 2016

0

  • Previous
  • 1
  • 2
  • ...
  • 31
  • 32
  • 33
  • ...
  • 115
  • 116
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy